{
  "docId": "019dd923-622c-750b-8b9a-21918ac10c17",
  "docSlug": "f3db2294dcf9",
  "documentTitle": "Harmony Biosciences (HRMY)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-03-28 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 30,
  "pageCount": 366,
  "prevPage": 29,
  "nextPage": 31,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a 'villain' narrative style to attack the legitimacy of Harmony Biosciences' IP.",
  "elementsJson": [
    "paragraph",
    "screenshot"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-21918ac10c17/30",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17#slide-30",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "The compound is so old that the three patents Harmony asserts are a sham.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64d0-7099-9cca-a94e04f704fd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.86,
        "x": 0.07,
        "y": 0.68
      },
      "kind": "image",
      "text": "Chemical structures from the paper",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cab7ef96-097c-46c7-ac99-9406030ce868",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.07,
        "y": 0.52
      },
      "kind": "image",
      "text": "Development of a New Class of Nonimidazole Histamine H3 Receptor Ligands with Combined Inhibitory Histamine N-Methyltransferase Activity",
      "attrs": null,
      "subkind": "screenshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cbeab39a-b763-4141-a619-6ca044ce8c8f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "paragraph",
      "text": "Pitolisant is the first and only H3 receptor antagonist/inverse agonist on the market for a reason – virtually every major pharma company tried to develop one for decades, with a 100% failure rate due to a fatally flawed mechanism of action and pharmacokinetic profile, lack of efficacy, and toxicity. The elephant in the room is self-evident: how did a small French lab miraculously succeed when over a dozen global pharma players failed, and why did no other pharma company license it until Jeff Aronin came along? Pitolisant’s structure was published in 2002 and we think it was first synthesized in the 1990’s, meaning it sat for a quarter-century with no takers. The compound is so old that the three patents Harmony asserts are a sham. We located a 2002 paper that published the molecule’s structure under a different name, creating prior art that would instantly invalidate the IP if we challenged in an Inter Partes Review.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0ba31fb0-6fa4-463a-94cf-67bd84777c67",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "Jean-Charles Schwartz paper submitted for publication in 2001 - table shows same molecule as pitolisant",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64d0-7099-9cca-ad5f550e2c1d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.25,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: https://pubmed.ncbi.nlm.nih.gov/11855993/",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5d213d8c-180b-4dfc-9f08-0fd0cd38490c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.86,
        "x": 0.07,
        "y": 0.47
      },
      "kind": "source-note",
      "text": "Jean-Charles Schwartz paper submitted for publication in 2001 - table shows same molecule as pitolisant",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8c68edf8-8af9-4f26-9248-f0eee76d8000",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "06a032c4-9896-4cd1-8b58-4d47253efa93",
      "evidence": "The slide explicitly claims the patents are a 'sham' and provides evidence of prior art to invalidate them.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 30,
      "from": 11,
      "beatId": "d0905c6f-1d0c-46ed-96fd-5548f20fae57",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Monster",
      "beatSlug": null,
      "evidence": "The document presents the 'monster' of the company's troubled drug and financial reporting",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 30,
      "from": 20,
      "name": "Aha Moment",
      "slug": "03-aha-moment",
      "bestFor": "Data-heavy sections, research findings, analytical arguments",
      "matchId": "b545ff30-50fa-4d68-abe5-bb3c4c439c61",
      "evidence": "The document presents a series of testimonials and data that build a case against the company",
      "position": 0,
      "objective": "To reveal the truth about the company's troubled drug and financial reporting",
      "structure": "The Problem/Question -> What the Data Shows -> The Insight",
      "confidence": 0.8,
      "description": "Establish a tension, present data, then deliver the insight that changes everything"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}